Keyword: Claire McCaskill
Sen. Sanders said it's time for Congress to force CEOs to testify on the opioid crisis as lawyers negotiate a potential settlement.
Current legislation doesn't include axing pharma's advertising deduction, but paying for other tax breaks may put it on the chopping block.
Five more lawmakers are piling on Allergan for the company's controversial tribal licensing deal.
Confronted with an investigation into its Vivitrol marketing, Alkermes contends it’s just trying to help the U.S. get control of the opioid crisis.
Sen. Claire McCaskill is moving to shut down the "brazen loophole" exposed in Allergan's tribal licensing deal.
Sen. Claire McCaskill is wondering whether Allergan's recent tribal licensing agreement is in agreement with PhRMA's mission.
Insys Therapeutics is the focus of a new congressional report detailing some former employees' sales techniques for powerful painkiller Subsys.
Democrats rolled out their new economic agenda Monday, calling it a “Better Deal.” For consumers, maybe. For the pharma industry, not so much.
Ohio’s attorney general is going after drugmakers for alleged “fraudulent marketing practices” on opioid painkillers.
The painkiller Ofirmev doubled in price after Mallinckrodt bought it—and it's the latest investigative target of Sen. Claire McCaskill. But this probe isn’t so cut-and-dried.